Press Releases

March 15, 2018
— Phase 3 PFIC trial of IBAT inhibitor A4250 planned to initiate in spring 2018 — — Elobixibat approved in Japan , becoming the first IBAT inhibitor approved in the world — — ~$200 million current cash balance expected to be sufficient to fund operations into 2021 — — Management to host conference